Axsome Therapeutics Q2 revenue rises on AUVELITY growth
AXSM•Analyst sentiment and valuation
The current average analyst rating on the shares is "buy," with 21 "strong buy" or "buy" ratings, one "hold," and no "sell" or "strong sell."
The median 12-month price target is $272.00, about 27.9% above the August 7 closing price of $212.74. The stock recently traded at 76 times next-12-month earnings, down from a P/E of 124 three months ago.
Outlook for the rest of the year
Axsome said it expects commercial momentum to build over the balance of the year, especially for AUVELITY. The company said it believes current cash is sufficient to fund operations into cash flow positivity.
It also expects topline results from the ENGAGE Phase 3 trial in binge eating disorder in the fourth quarter of 2026.
Q2 revenue rises but misses estimates
Axsome Therapeutics said second-quarter revenue rose 46% year over year, though it missed analyst expectations. The company reported a net loss for the quarter that widened slightly from a year earlier.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Revenue | Miss | $218.38 mln | $221.23 mln (18 Analysts) |
| Q2 Loss Per Share | $0.99 | ||
| Q2 Net Loss | $51.31 mln | ||
| Q2 Operating Expenses | $268.02 mln | ||
| Q2 Operating Income | -$49.65 mln | ||
| Q2 Pretax Loss | $51.19 mln |
